He describes the label and what he believes it means for the therapy's competitive position. Plus, the commercial plans that have put...

Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 in ADH1 and investing in early science.

BridgeBio's Neil Kumar shares experiences that may be good learnings for other drug developers and discusses his company's unique model.